Actively Recruiting
Partial Prostate Salvage High Dose Rate Brachytherapy
Led by British Columbia Cancer Agency · Updated on 2026-02-02
30
Participants Needed
1
Research Sites
991 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of inability to deliver sufficient dose through external beam techniques. These patients respond well to re-irradiation using brachytherapy with about 50% of selected patients remaining free of recurrence 5 years after salvage. Advanced imaging using multiparametric Magnetic Resonance Imaging (mpMRI) allows identification of the site of recurrence, permitting partial prostate salvage brachytherapy. There is extensive literature on Low Dose Rate salvage brachytherapy but less on High Dose Rate.
CONDITIONS
Official Title
Partial Prostate Salvage High Dose Rate Brachytherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male aged over 45 years with life expectancy greater than 10 years
- Previous external beam radiotherapy up to specified doses or low dose rate brachytherapy with recurrence in an under-treated area
- At least 3 years since prior radiotherapy
- No late toxicity from prior radiotherapy of grade 2 or higher
- Rising PSA above nadir + 2 ng/ml but less than 10 ng/ml
- PSA doubling time longer than 6 months
- Negative staging scans including CT abdomen/pelvis and bone scan or PSMA PET scan
- Able to undergo multiparametric MRI with endorectal coil
- Radiographic evidence of a single dominant intraprostatic lesion
- Biopsy confirmation of the lesion reviewed by specialized pathologist
- Able and willing to provide informed consent
- History and physical exam within 90 days before registration
- ECOG performance status 0-1
- International Prostate Symptom Score less than 16 or adequate voiding study results
- No prior transurethral prostatic resection
- Lesion suitable for HDR brachytherapy implant with planning target volume ideally less than 65% of prostate volume
- No history of inflammatory bowel disease or previous rectal surgery
- Suitable for anesthesia (spinal or general)
- INR less than 2.5 and platelet count above 75 x 10^9/L
- Androgen deprivation therapy may be used at oncologist's discretion
You will not qualify if you...
- Failure to meet all inclusion criteria
- Unable to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
BCCA Center for the Southern Interior
Kelowna, British Columbia, Canada, V1Y 5L3
Actively Recruiting
Research Team
J
Juanita Crook, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here